Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
Rhea-AI Summary
Longeveron (NASDAQ: LGVN) will report third quarter 2025 financial results and provide a business update on Tuesday, November 4, 2025 after U.S. markets close. The company will host a conference call and webcast the same day at 4:30 p.m. ET. Dial-in: 1.877.407.0789 with Conference ID 13755997. A replay of the webcast will be available in the Events & Presentations section of the company website following the call.
Positive
- None.
Negative
- None.
News Market Reaction – LGVN
In the Oct 28 session, LGVN gained 1.30%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report third quarter 2025 financial results and provide a business update on Tuesday, November 4, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.
| Conference Call and Webcast Details: | ||
| Conference Call Number: | 1.877.407.0789 | |
| Conference ID: | 13755997 | |
| Call me™ Feature: | Click Here | |
| Webcast: | Click Here | |
An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric Dilated Cardiomyopathy (DCM), and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
